Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 479 (ganitumab) plus gemcitabine vs placebo plus gemcitabine in first-line therapy for unresectable locally advanced pancreatic adenocarcinoma
2010-023978-39Phase 2Terminated
- Sponsor
- Amgen
- Start
- May 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pancreatic adenocarcinoma (PDAC) comparing Ganitumab + gemcitabine with Placebo + gemcitabine (2 arms). Primary endpoint: Progression-free survival. Started May 2011; status: terminated.
02
Drugs
ganitumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2010-023978-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023978-39.